医学
甲状腺机能正常
队列
内科学
再现性
抗体
甲状腺疾病
甲状腺过氧化物酶
甲状腺
免疫分析
多路复用
临床实习
甲状腺炎
胃肠病学
免疫学
临床意义
格雷夫斯病
疾病
四分位间距
病理
作者
Kenneth Dale Burman,Lowell R. Schmeltz,Yoko Momoyama,Feyza Erenler,Samer Nakhle,Fabian A. Mendoza-Ballesteros,Arvind Krishna,Meera Amar,David G. Robertson,Catherine Anastasopoulou,Mark Armin Lupo,Michael Howard Shanik,John Y. Jun,Trisha D. Cubb,Olga Senashova,Andrew J. Behnke,David L. Brodbeck,Sandra Yasavul,Peter Dilba,Oliver Lorenz
标识
DOI:10.1515/cclm-2026-0044
摘要
Abstract Objectives Use of polyclonal antibodies (pAbs) in immunoassays has limitations related to inter-batch variation and supply chain stability which may affect assay reproducibility, scalability, and sustainability. The Elecsys ® Anti-TPO II assay, where the pAb of the Elecsys Anti-TPO assay has been replaced with two monoclonal antibodies, aims to address these factors. We evaluated analytical and clinical performance for Elecsys Anti-TPO II using Cobas ® e 601 and e 801 analyzers. Methods Repeatability, intermediate precision, and reproducibility were assessed over 5 days at three sites, within/between multiple reagent lots and analyzers. Method comparisons were performed against Elecsys Anti-TPO and three other immunoassays, using 218 serum samples covering the measuring range. The clinical cutoff was derived from 85 patients with confirmed Hashimoto thyroiditis (HT); reference intervals determined using samples from 230 healthy euthyroid individuals. Clinical performance was evaluated in 608 patients with confirmed HT, Graves disease, non-autoimmune thyroid diseases, or non-thyroid autoimmune diseases. Results Elecsys Anti-TPO II demonstrated high precision (standard deviations for repeatability, intermediate precision, and reproducibility <1.6 IU/mL for measurements ≤30 IU/mL; coefficients of variation <7 % for measurements >30 IU/mL) and improved semi-quantitative agreement (94.0–97.7 %) with comparator assays, vs. Elecsys Anti-TPO (88.5–90.8 %). The 95th percentile of the reference range cohort was <8 IU/mL; specificity in this cohort was 97.4 % (cutoff of ≥20 IU/mL). Clinical sensitivity for HT was 90.5 %; clinical specificity in disease control groups was 90.7 %. Conclusions Elecsys Anti-TPO II offers robust analytical and clinical performance, supporting its utility in diagnosing auto-immune thyroid diseases in routine clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI